Basic Phenergan Information

• INN (International Nonproprietary Name): Promethazine hydrochloride
• Brand Names Available In Canada (English): not specified
• ATC Code: R06AD02
• Forms & Dosages: Tablets 10 mg and 25 mg; Elixir 1 mg/mL (100 mL bottle); suppositories 12.5 mg, 25 mg, 50 mg (less commonly available)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription medication (Rx) in most countries; typically prescription-only

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and clinicians ask whether new studies change how promethazine is used in Canada.

High‑quality randomized controlled trials isolating promethazine specifically are limited between 2022 and mid‑2024.

Most recent evidence comes from post‑marketing safety reviews and comparative observational research reported by regulators and academic groups.

Canadian practice guidance echoes international regulators (TGA, MHRA, Health Canada) summarizing benefits and risks.

Main Outcomes

Analyses show promethazine delivers effective short‑term symptom control for nausea and motion sickness.

Comparative work finds inconsistent superiority versus other first‑generation antihistamines for many indications.

No robust evidence supports long‑term use for chronic insomnia or chronic nausea beyond situational needs.

Safety Observations

Regulatory summaries and observational literature emphasise respiratory depression risk in children under two years and increased sedation in older adults.

Post‑marketing reports highlight fall risk, cognitive impairment and cumulative anticholinergic burden in polypharmacy.

Clinical trend in 2023–24 favours safer alternatives for chronic indications while retaining promethazine for acute, situational use.

Clinical Mechanism Of Action

Layman’s Explanation

People often want a simple explanation when given a tablet for travel sickness or allergy symptoms.

Phenergan works by blocking histamine signals that can cause itching and watery eyes, and it produces strong sedation that helps with nausea and anxiety.

Think of it as an older antihistamine that also calms the nervous system and dries up secretions.

Scientific Breakdown

Promethazine is a phenothiazine derivative with primary H1 receptor antagonism, classified under ATC R06AD02.

H1 antagonism produces antihistaminic and sedative effects which reduce vestibular signalling related to motion sickness.

Receptor-Level Actions

Blockade of H1 receptors reduces peripheral allergic symptoms and central vestibular input that triggers nausea.

Anticholinergic (muscarinic) activity contributes to antiemetic effects and drying of secretions but also causes dry mouth, blurred vision and constipation.

There is weak dopamine receptor antagonism which may add antiemetic benefit but carries a small risk of extrapyramidal reactions in susceptible patients.

Pharmacokinetics (Brief)

Oral tablets and elixir are well absorbed and cross into the central nervous system producing sedation.

Half‑life is variable and tends to be prolonged in hepatic impairment and in older adults, so dose reductions are advised for these groups.

Scope Of Approved & Off-Label Use

Health Canada Approvals (DIN-Based)

Promethazine products marketed internationally include Phenergan and other brand names; specific Canadian DINs should be checked in Health Canada’s Drug Product Database.

Typical approved indications are allergic conditions, motion sickness prophylaxis, short‑term sedation (including pre‑operative), and symptomatic nausea and vomiting.

Products are usually prescription‑only, and the exact monograph, dosing and approved uses depend on the specific DIN and manufacturer.

Notable Off‑Label Trends In Canadian Practice

Canadian clinicians sometimes use promethazine off‑label as an adjunct for palliative nausea where other options are limited.

Occasional use appears for acute migraine‑associated nausea and short‑term night‑time sedation, driven by clinical experience rather than strong trial data.

Provincial formularies commonly restrict coverage to listed indications, so check ODB, PharmaCare or RAMQ rules before prescribing for off‑label uses.

Dosage Strategy

General Dosing Per Health Canada Monographs

Standard adult dosing commonly used in product monographs is 10–25 mg at night or 10 mg two to three times daily for allergic states.

For motion sickness, a common regimen is 25 mg the night before travel or 25 mg one to two hours before departure.

For nausea and vomiting, adult doses of 25–50 mg every four to six hours as needed are typical, with pre‑operative sedation often 25–50 mg once.

Condition‑Specific Dosing Adjustments

Paediatric dosing for older children is usually 5–15 mg at night or divided doses, but promethazine must not be used in children under two years due to fatal respiratory depression risk.

Reduce doses in elderly patients and in those with liver or kidney impairment because of increased sensitivity and longer half‑life.

Use the lowest effective dose in patients taking multiple anticholinergic or sedating medicines and document indication and monitoring plans for any off‑label use.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include hypersensitivity to promethazine or other phenothiazines and use in children under two years due to respiratory depression risk.

Do not give promethazine to patients who are comatose or have severe CNS or respiratory depression.

Use caution in elderly patients, in severe hepatic or renal impairment, in seizure disorders, narrow‑angle glaucoma, prostatic hypertrophy, and cardiovascular disease.

Adverse Effects (Post‑Market Reports)

Common adverse effects are sedation and drowsiness, dizziness, dry mouth, blurred vision and constipation.

Post‑marketing surveillance from 2022–24 highlights respiratory depression in infants, increased falls and confusion in older adults, and higher anticholinergic burden with chronic use.

Pharmacists should counsel patients about driving safety, avoidance of alcohol and other CNS depressants, and review cumulative anticholinergic scores in polypharmacy.

Interaction Mapping

Food Interactions Common In Canadian Diet

Alcohol and cannabis, both commonly used in Canada, potentiate promethazine’s central sedation and respiratory depression and should be avoided while taking the medicine.

Grapefruit juice is not a primary concern for promethazine, though fatty meals may affect absorption timing and onset of action.

Drug Combinations Flagged By Health Canada

Major drug interactions include other CNS depressants such as opioids, benzodiazepines and sedating antidepressants which increase drowsiness and respiratory depression risk.

Combine promethazine cautiously with other anticholinergic agents to avoid excessive dry mouth, constipation and cognitive impairment, and avoid concomitant MAO inhibitors due to enhanced anticholinergic and sedative effects.

Monitor ECG when combining promethazine with known QT‑prolonging medications in high‑risk patients, and be cautious with drugs that lower seizure threshold.

Patient Experience Analysis

Canadian Survey Data

Many patients report fast symptom relief for motion sickness and acute nausea after a single dose of Phenergan, but they also mention predictable drowsiness.

Community pharmacy surveys from 2022–24 indicate pharmacists frequently counsel patients about sedation, driving safety and alternatives for chronic use.

Forum & Community Pharmacy Trends

Online reviews commonly praise promethazine for travel nausea control but note residual daytime sedation and next‑day impairment in some users.

Caregivers strongly warn against use in infants, and older patients often report dizziness and increased fall risk, which aligns with regulatory safety messaging and informs pharmacist risk‑benefit discussions.

Distribution & Pricing Landscape

National Pharmacy Chains

Promethazine is stocked at major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, though it remains prescription‑only and availability can vary by store.

Pharmacists may limit supply from shelves as part of risk management and counselling requirements.

Online Pharmacy Availability & Provincial Restrictions

Online pharmacies and telehealth services can supply promethazine prescriptions after verification of indication and DIN details are checked against Health Canada records.

Provincial formularies like Ontario Drug Benefit, BC PharmaCare and RAMQ usually restrict coverage to specific indications and many patients pay out‑of‑pocket or apply for exceptions.

In our online pharmacy, phenergan is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

Generic promethazine pricing in the United States can be lower for uninsured purchasers, but importation rules and prescription requirements apply and patients should be cautious about differing formulations and label languages.

Bilingual labelling and DIN compliance are mandatory for products marketed in Canada.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

Choose alternatives based on the clinical context: diphenhydramine or chlorpheniramine for short‑term antihistamine needs, scopolamine patches for motion sickness, and ondansetron for stronger nausea control in chemotherapy or post‑op settings.

Pros And Cons Checklist

• Promethazine: Effective acute antiemetic and sedative but higher anticholinergic and cognitive risk with chronic use.
• Diphenhydramine: Similar sedation and OTC availability but also anticholinergic burden.
• Ondansetron: Stronger evidence for chemo/post‑op nausea, minimal sedation, higher prescription cost.
• Scopolamine Patch: Useful for motion sickness without oral sedation, but patch side effects and application considerations apply.

Match the choice to patient age, comorbidities, driving or occupational needs and formulary coverage when counselling at the pharmacy.

Regulatory Status

Health Canada Approval Process

Promethazine products must meet Health Canada approval pathways and are assigned a Drug Identification Number that links to product monographs and conditions of sale.

Health Canada updates labels and safety communications based on manufacturer submissions, clinical data and post‑market surveillance, for example highlighting paediatric respiratory warnings.

DIN And Bilingual Labelling Rules

Canadian labelling requires bilingual (English/French) information, clear dosing, contraindications and storage instructions on marketed products.

Promethazine is generally prescription‑only in Canada and provincial formularies or hospital policies may further limit use.

Consolidated FAQ

Q: Can I buy Phenergan without a prescription in Canada?

A: Generally no — promethazine is prescription‑only; confirm with your pharmacist and check provincial rules.

Q: Is Phenergan safe for children?

A: It must not be used in children under two years due to the risk of fatal respiratory depression.

Q: Can I drive after taking promethazine?

A: Avoid driving or operating machinery until you know how sedating it is for you, and do not mix with alcohol or opioids.

Q: Will my provincial drug plan cover it?

A: Coverage varies across Ontario Drug Benefit, PharmaCare and RAMQ and may be limited to specific indications; check the formulary for criteria.

Q: What should I tell my pharmacist?

A: Provide a full medication list, known allergies, pregnancy or breastfeeding status and details about your occupation or driving needs.

Visual Guide

Designers and clinicians will want a compact infographic summarising dosage, provincial coverage and purchase channels for patients.

Include a quick‑dose card listing tablet/elixir strengths (10 mg, 25 mg; 1 mg/mL elixir), adult and paediatric ranges and a clear contraindication banner for children under two years.

Create a provincial coverage map icon set for ODB, BC PharmaCare and RAMQ that shows likely coverage versus private pay.

Add a risk matrix highlighting high‑risk groups — infants, elderly, hepatic impairment and polypharmacy — with monitoring checkpoints for pharmacists.

Include a purchase channels flowchart from prescription to community pharmacy and online/telepharmacy, plus a DIN lookup QR code linking to Health Canada.

Storage & Transport

Canadian Household Guidelines

Store promethazine below 30°C, out of direct light and in its original packaging, and keep elixir bottles tightly capped and out of reach of children.

Do not refrigerate unless the manufacturer specifies otherwise and avoid prolonged exposure to extreme heat or cold during travel.

Cold‑Chain Storage Where Applicable

Promethazine does not typically require cold‑chain storage, but maintain standard pharmaceutical transport conditions when shipping or travelling with medication.

For cross‑border travel, carry medication in a labelled container with the prescription note to avoid issues with customs or airlines.

Dispose of unused medicine at pharmacy take‑back programs rather than household trash to reduce accidental ingestion risk.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists should confirm the indication, assess age and weight for paediatric patients, and review the full medication list for CNS depressants or other anticholinergic agents.

Counsel patients about sedation and driving restrictions, provide dosing conversion between tablet and elixir forms, and document counselling and the planned review date.

Provincial Health Authority Guidance

Follow provincial formularies for coverage and Health Canada monograph contraindications, and use institutional protocols in hospitals for antiemetic selection and pre‑operative sedation.

Start with the lowest effective dose, avoid alcohol and cannabis, and monitor for excessive sedation, urinary retention or respiratory difficulty.

Record the reason for prescription, counselling points and arrange a scheduled reassessment to limit long‑term anticholinergic burden.

Delivery Across Canada (English)